July 30, 2020
Medical artificial intelligence (AI) solution development company VUNO gained the Class IIa CE markings for five of their AI solutions.
The five CE marked solutions are: VUNO Med®-BoneAge™, VUNO Med®-DeepBrain™, VUNO Med®-Chest X-Ray™, VUNO Med®–Fundus AI™, and VUNO Med®–LungCT AI™. These products can now be commercialized and sold in 27 member states of the European Union, the Acceding countries as well as EFTA states. They can also make inroads into countries that recognize the European CE mark such as those in the Middle East, Asia, South and Central America, and Africa.
VUNO was assessed and deemed to meet EU safety and health protection requirements by a Notified Body based on a more stringent clinical validation standards and medical device guidelines. The efficacy and safety of those products demonstrated by a series of clinical research results and papers published in high impact journals and prestigious international seminars were of great help to satisfy the strict requirements.
Of the five MFDS (Ministry of Food and Drug Safety) approved products, four products (VUNO Med®-Fundus AI™, VUNO Med®-Chest X-ray™, and VUNO Med® - BoneAge™ and VUNO Med® Lung CT AI™) received regulatory approval based on the proven effectiveness of performance through clinical trials. With such a robust portfolio, it is anticipated that VUNO Med solutions are to be used as key diagnostic supporting tools across many different medical environments overseas.
Hyun-Jun Kim, CEO of VUNO explained that, "We have been taking proper measures to ensure that VUNO's products obtain classification commensurate with their intended purposes as medical diagnostic supporting tools". He also added that, "In this sense, obtaining CE certification for all five products holds a great significance, and this will be able to accelerate our push for much anticipated global supply of VUNO Med series all around the world."
VUNO has been graining great traction at home and abroad and is ready to deploy the CE marked products to international business partners and clients across different markets.
Thanks for subscribing to our newsletter.